SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9109)9/11/2003 12:13:30 PM
From: Icebrg  Read Replies (1) | Respond to of 52153
 
>>Interesting analysis>>

Yes, but I have since deleted it. I "have to" think through this once more before I post it. Even if it is someone else's conclusions.

It is difficult as the subgroup is included in the full group which is included in the complete group.

Erik



To: Biomaven who wrote (9109)9/11/2003 1:01:55 PM
From: BulbaMan  Read Replies (1) | Respond to of 52153
 
Peter: Would much appreciate your comments on the CC. To me, at least, they sounded pretty confident of FDA approval. And, neither Aventis or Genta seem likely to be companies that would go out on a limb for a drug they knew was ineffective.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News